Table 1.
Demographics for the study participants
| Demographics | ALL-median (IQR) |
APOE4 carriers (n = 34) |
APOE4 noncarriers (n = 29) |
||
|---|---|---|---|---|---|
| AD | CN | AD | CN | ||
| Age (y)b | 70.57 (12.93) | 75.23 (7.97) | 68.05 (16.59) | 76.27 (11.50) | 64.88 (18.08) |
| Sex (m/f)a,b | 37/26 | 11/7 | 9/7 | 10/5 | 7/7 |
| Education (y) | 16 (5.5) | 16 (5) | 14 (2.5) | 14 (5.25) | 16 (2) |
| Diagnosis (AD/control)a | 33/30 | 18 | 16 | 15 | 14 |
| MMSEb | 28 (5) | 25.5 (4.5) | 29 (2) | 27 (7.5) | 30 (1) |
| CDR score (0/0.5/1)a | 30/25/8 | 1/13/4 | 15/1/0 | 0/11/4 | 14/0/0 |
| Aβ-42 pg/mLa,c,e | 529.667 (312.94) | 319.45 (235.74) | 581.07 (278.07) | 505.19 (265.59) | 643.08 (139.18) |
| T-Tau pg/mLa,b,d | 361.9 (412.51) | 553.18 (373.03) | 309.51 (292.43) | 468.25 (349.98) | 202.99 (91.26) |
| P-Tau pg/mL | 61.892 (43.87) | 78.18 (69.38) | 60.45 (34.68) | 72.56 (46.29) | 49.13 (24.74) |
| TNF-α pg/mLe | 0.0939 (0.0809) | 0.107 (0.081) | 0.11 (0.114) | 0.09 (0.0518) | 0.0806 (0.0275) |
Significance was tested using Mann-Whitney test.
Key: Aβ, amyloid-β; AD, Alzheimer’s disease; APOE4, apolipoprotein E-ε4; CN, cognitively normal; TNF-α, tumor necrosis factor-alpha.
a
indicates significant difference between APOE4 carrier groups.
b
indicates significant difference between AD/CN groups.
c
indicates significant differences between APOE4 carrier versus noncarrier subgroups of AD group.
d
indicates significant differences between APOE4 carrier versus non-carrier subgroups of CN group.
e
indicates significant difference between CN in APOE4 carrier group and AD in APOE4 noncarrier group. APOE4 + participants carried a genotype of APOE3/4. APOE4-participants carried a genotype of APOE3/3.